Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms
BioSpace
Jefferies expects Moderna to have around seven commercial products in the coming years which, along with a projected 10% revenue growth, could help the company break even in 2028.
pharminent
June 26, 2026 (Last updated: June 26, 2026)
BioSpace
Jefferies expects Moderna to have around seven commercial products in the coming years which, along with a projected 10% revenue growth, could help the company break even in 2028.
